US private equity house Genstar Capital is reportedly hoping to reach a $5bn price tag for pharmaceuticals and regulatory consulting business Advarra through a potential sale.
The firm picked up Advarra from fellow buyout investor Linden Capital Partners in 2019, in a deal believed to value the business at about $1.3bn.
Genstar raced to an $11.7bn close for its tenth fund last year – a huge increase on the already weighty $5.5bn Fund IX it closed in 2019.
Recent deals from the firm have included buying Arrowhead Engineered Products, a global provider of replacement parts for motorised vehicles and equipment, from The Riverside Company and Investcorp.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.